A Multifactorial Approach to Hepatobiliary Transporter Assessment Enables Improved Therapeutic Compound Development
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
The bile salt export pump (BSEP) is expressed at the canalicular domain of hepatocytes, where it serves as the primary route of elimination for monovalent bile acids (BAs) into the bile canaliculi. The most compelling evidence linking dysfunction in BA transport with liver injury in humans is found with carriers of mutations that render BSEP nonfunctional. Based on mounting evidence, there appears to be a strong association between drug-induced BSEP interference and liver injury in humans; however, causality has not been established. For this reason, drug-induced BSEP interference is best considered a susceptibility factor for liver injury as other host- or drug-related properties may contribute to the development of hepatotoxicity. To better understand the association between BSEP interference and liver injury in humans, over 600 marketed or withdrawn drugs were evaluated in BSEP expressing membrane vesicles. The example of a compound that failed during phase 1 human trials is also described, AMG 009. AMG 009 showed evidence of liver injury in humans that was not predicted by preclinical safety studies, and BSEP inhibition was implicated. For 109 of the drugs with some effect on in vitro BSEP function, clinical use, associations with hepatotoxicity, pharmacokinetic data, and other information were annotated. A steady state concentration (C(ss)) for each of these annotated drugs was estimated, and a ratio between this value and measured IC₅₀ potency values were calculated in an attempt to relate exposure to in vitro potencies. When factoring for exposure, 95% of the annotated compounds with a C(ss)/BSEP IC₅₀ ratio ≥ 0.1 were associated with some form of liver injury. We then investigated the relationship between clinical evidence of liver injury and effects to multidrug resistance-associated proteins (MRPs) believed to play a role in BA homeostasis. The effect of 600+ drugs on MRP2, MRP3, and MRP4 function was also evaluated in membrane vesicle assays. Drugs with a C(ss)/BSEP IC₅₀ ratio ≥ 0.1 and a C(ss)/MRP IC₅₀ ratio ≥ 0.1 had almost a 100% correlation with some evidence of liver injury in humans. These data suggest that integration of exposure data, and knowledge of an effect to not only BSEP but also one or more of the MRPs, is a useful tool for informing the potential for liver injury due to altered BA transport.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Considering that mechanisms leading to alterations in bile-acid homeostasis are believed in part to be responsible for recent prominent late-stage clinical attritions and black box warnings of novel therapeutics, including examples such as CP-724,714 (Feng et al. 2009), tolvaptan (Slizgi et al. 2016), AMG-009 (Morgan et al. 2013), and TAK-875 (Wolenski et al. 2017)”
From Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury (2017) · cites this paper as Morgan et al. 2013
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guide for the Care and Use of Laboratory Animals: Eighth Edition
(2011) · doi:10.17226/12910 · Cited by 16,199
The 1996 Guide for the Care and Use of Laboratory Animals
Clark, J. D., Gebhart, G. F., Gonder, J. C., Keeling, M. E., & Kohn, D. F. (1997) · ILAR Journal · doi:10.1093/ilar.38.1.41 · Cited by 4,417
Concordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050 · cited 4×
“…the concordance between preclinical animal safety data and human clinical outcomes for 150 development compounds and found that hepatotoxicity ( 60% concordance) and cutaneous/hypersensitivity reactions ( 40% concordance) were the 2 poorest predicted adverse events (Olson et al., 2000).”
BackgroundInfluentialBile salt transporters: molecular characterization, function, and regulation
Trauner, M., & Boyer, J. L. (2003) · Physiological Reviews · doi:10.1152/physrev.00027.2002 · Cited by 999 · cited 3×
“To mitigate potential cytotoxicity, BA homeostasis is tightly regulated by metabolic, excretion, absorption, and feedback mechanisms to limit their intracellular accumulation (Trauner and Boyer, 2003).”
BackgroundStepan, A. F., Walker, D. P., Bauman, J., Price, D. A., Baillie, T. A., Kalgutkar, A. S., & Aleo, M. D. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200168d · Cited by 698
Stieger, B., Fattinger, K., Madon, J., Kullak-Ublick, G. A., & Meier, P. J. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70224-1 · Cited by 582
Fattinger, K. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.114667 · Cited by 509
The apical conjugate efflux pump ABCC2 (MRP2)
Nies, A. T., & Keppler, D. (2007) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-006-0109-y · Cited by 398
Dawson, S., Stahl, S., Paul, N., Barber, J., & Kenna, J. G. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.040758 · Cited by 343
Zollner, G., Marschall, H.-U., Wagner, M., & Trauner, M. (2006) · Molecular Pharmaceutics · doi:10.1021/mp060010s · Cited by 335
Cited by
Items 101–200 of 244
Paludetto, M., Stigliani, J., Robert, A., Bernardes‐Génisson, V., Chatelut, É., Puisset, F., & Arellano, C. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00205 · Cited by 24
Guo, C., Yang, K., Brouwer, K. R., Claire, R. L. S., & Brouwer, K. L. R. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.231928 · Cited by 23
“, 2013) MRP3 60 (IC50) (Morgan et al., 2013) 42 (IC50) (Morgan et al.”
InfluentialChan, R., & Benet, L. Z. (2018) · Toxicology Research · doi:10.1039/c8tx00016f · Cited by 28
Generaux, G. T., Lakhani, V., Yang, Y., Nadanaciva, S., Qiu, L., Riccardi, K. A., Di, L., Howell, B. A., Siler, S. Q., Watkins, P. B., et al. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.523 · Cited by 21
Current Concepts in Drug‐Induced Bile Salt Export Pump (BSEP) Interference
Kenna, J. G. (2014) · Current Protocols in Toxicology · doi:10.1002/0471140856.tx2307s61 · Cited by 22
“Consequently, CDF is added to SCH in the form of nonfluorescent but membrane-permeable CDF diacetate, which is cleaved intracellularly to release fluorescent CDF (Zamek-Gliszczynski et al., 2003; Nakanishi et al., 2011).”
BackgroundHafey, M. J., Houle, R., Tanis, K. Q., Knemeyer, I. W., Shang, J., Chen, Q., Baudy, A. R., Monroe, J. J., Sistare, F. D., & Evers, R. (2020) · Drug Metabolism and Disposition · doi:10.1124/dmd.120.000086 · Cited by 21
Srinivas, N. R. (2016) · General Physiology and Biophysics · doi:10.4149/gpb_2015050 · Cited by 22
Li, R., Niosi, M., Johnson, N., Tess, D. A., Kimoto, E., Lin, J., Yang, X., Riccardi, K. A., Ryu, S., El‐Kattan, A. F., et al. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.117.078790 · Cited by 22
“Competitive inhibition of four transporters was calculated independently based on simulated bosentan unbound plasma (for NTCP) or intracellular (for BSEP and MRP) concentrations and in vitro IC50 values (Leslie et al., 2007; Morgan et al., 2013).”
BackgroundMethodInfluentialSusukida, T., Sekine, S., Ogimura, E., Aoki, S., Oizumi, K., Horie, T., & Ito, K. (2015) · Toxicology in Vitro · doi:10.1016/j.tiv.2015.06.004 · Cited by 22
Burbank, M., Sharanek, A., Burban, A., Mialanne, H., Aerts, H., Guguen‐Guillouzo, C., Weaver, R. J., & Guillouzo, A. (2017) · Toxicological Sciences · doi:10.1093/toxsci/kfx062 · Cited by 20
“As observed earlier (Hartman et al., 2010; Kenna, 2014; Morgan et al., 2013), SIT also inhibited TCA and CDF efflux activity in HepaRG cells.”
InfluentialIn silico drug discovery: a machine learning-driven systematic review
Atasever, S. (2024) · Medicinal Chemistry Research · doi:10.1007/s00044-024-03260-w · Cited by 33
Maiuri, A. R., Wassink, B., Turkus, J., Breier, A. B., Lansdell, T. A., Kaur, G., Hession, S. L., Ganey, P. E., & Roth, R. A. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.242354 · Cited by 23
“based on direct effects of drugs on hepatocellular biochemistry and/or on physicalchemical characteristics of drugs (Aleo et al., 2014; Chen et al., 2013 and 2014; Choi et al., 2015; Khetani et al., 2013; Low et al., 2011; Morgan et al., 2013; Sakatis et al., 2012; Schadt et al., 2015; Susukida et al., 2015; Thompson…”
MethodSaran, C., Fu, D., Ho, H. S. S., Klein, A., Fallon, J. K., Honkakoski, P., & Brouwer, K. L. R. (2022) · Scientific Reports · doi:10.1038/s41598-022-18174-z · Cited by 22
Garzel, B., Zhang, L., Huang, S. M., & Wang, H. (2019) · Current Drug Metabolism · doi:10.2174/1389200220666190709170256 · Cited by 24
Assessing the Risk of Drug-Induced Cholestasis Using Unbound Intrahepatic Concentrations
Riede, J., Poller, B., Huwyler, J., & Camenisch, G. (2017) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.074179 · Cited by 20
“, Csys,u of atorvastatin and rosiglitazone), our parameters significantly deviate from previous studies (Dawson et al., 2012; Morgan et al., 2013; Shah et al., 2015).”
ResultHilpert, J., Groettrup‐Wolfers, E., Kosturski, H., Bennett, L., Barnes, C. L. K., Gude, K., Gashaw, I., Reif, S., Steger‐Hartmann, T., Scheerans, C., et al. (2023) · Drugs in R&D · doi:10.1007/s40268-023-00427-5 · Cited by 19
“This absence reflects the variable sensitivity of different animal species to the modulation of bile salt content in hepatocytes [28].”
BackgroundInfluentialMachine Learning Techniques Applied to the Study of Drug Transporters
Kong, X., Lin, K., Wu, G., Tao, X., Zhai, X., Lv, L., Dong, D., Zhu, Y., & Yang, S. (2023) · Molecules · doi:10.3390/molecules28165936 · Cited by 20
Stieger, B., & Mahdi, Z. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.03.023 · Cited by 19
Horiuchi, S., Kuroda, Y., Oyafuso, R., Komizu, Y., Takaki, T., Maeda, K., & Ishida, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-19469-x · Cited by 20
Howell, B. A., Siler, S. Q., Barton, H. A., Joshi, E., Cabal, A., Eichenbaum, G. M., & Watkins, P. B. (2016) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2017.04.001 · Cited by 18
Ryan, J., Morgan, R. E., Chen, Y., Volak, L. P., Dunn, R. T., & Dunn, K. W. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.117.079277 · Cited by 18
“The practice of relating in vitro potencies to exposure values, such as concentration at steady state, has been shown to improve the correlation with hepatotoxicity outcome (Dawson et al., 2012; Morgan et al., 2013).”
BackgroundMethodSelf-citationRodríguez-Pérez, R., & Gerebtzoff, G. (2021) · Artificial Intelligence in the Life Sciences · doi:10.1016/j.ailsci.2021.100027 · Cited by 19
Mao, X., Xu, M., Yan, X., Chen, L., Lin, N., & Zhang, Y. (2024) · hLife · doi:10.1016/j.hlife.2024.01.004 · Cited by 17
de Bruijn, V. M. P., Rietjens, I. M. C. M., & Bouwmeester, H. (2022) · Archives of Toxicology · doi:10.1007/s00204-022-03345-8 · Cited by 15
Assessment of liver injury potential of investigational medicines in drug development
Chalasani, N., Hayashi, P. H., Luffer, D. R., Regev, A., & Watkins, P. B. (2026) · Hepatology · doi:10.1097/hep.0000000000001281 · Cited by 18
Holmstock, N., Oorts, M., Snoeys, J., & Annaert, P. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.117.079467 · Cited by 17
“Also, transporter-expressedmembrane vesicles and transporter-transfected cell lines are regularly used to screen for efflux transporter inhibitors (Förster et al., 2008; Lechner et al., 2010; Morgan et al., 2013).”
BackgroundPredicting drug-induced cholestasis: preclinical models
Petrov, P., Fernández-Murga, M. L., López-Riera, M., Gómez-Lechón, M. J., Castell, J. V., & Jover, R. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1487399 · Cited by 15
Yang, F., Takeuchi, T., Tsuneyama, K., Yokoi, T., & Oda, S. (2019) · Toxicological Sciences · doi:10.1093/toxsci/kfz088 · Cited by 14
Jain, S., & Ecker, G. F. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9420-5_26 · Cited by 16
Ji, H., Song, N., Ren, J., Li, W., Zhang, L., Xu, B., Li, H., Shen, G., & Li, H. (2020) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00503 · Cited by 14
Zhou, L., Pang, X., Jiang, J., Zhong, D., & Chen, X. (2017) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.074104 · Cited by 13
“mediating the transport of bile acids, especially the sulfated bile acids (Akita et al., 2001; Morgan et al., 2013; Rodrigues et al., 2014).”
BackgroundGoracci, L., Valeri, A., Sciabola, S., Aleo, M. D., Moritz, W., Lichtenberg, J., & Cruciani, G. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00364 · Cited by 14
Aleo, M. D., Aubrecht, J., Bonin, P. D., Burt, D. A., Colangelo, J. L., Luo, L., Schomaker, S., Swiss, R. L., Kirby, S., Rigdon, G. C., et al. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.467 · Cited by 13
“Morgan et al.40 has shown with a larger collection of marketed drugs that a ratio of a drug's total systemic steady‐state exposure to BSEP IC50 value >0.1x highlights an enhanced risk area associated with human DILI.41 This compound was further modeled using DILIsym® software due to complexities of trying to understan…”
BackgroundInfluentialWang, T., Liu, Y., An, C., Mueed, A., Wu, T., Jia, Z., Li, S., Ma, H., Su, L., & Liu, S. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.136703 · Cited by 16
In vitro test battery for testing molecular initiating events in chemical-induced cholestasis
Maerten, A., Drees, A., Jiang, J., Sanz-Serrano, J., Devisscher, L., & Vinken, M. (2025) · Toxicology · doi:10.1016/j.tox.2025.154210 · Cited by 13
Lapham, K., Novak, J. J., Marroquin, L. D., Swiss, R. L., Qin, S., Strock, C. J., Scialis, R. J., Aleo, M. D., Schroeter, T., Eng, H. F., et al. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00262 · Cited by 12
Mouse precision-cut liver slices as an ex vivo model to study drug-induced cholestasis
Karsten, R. E. H., Krijnen, N., Maho, W., Permentier, H. P., Verpoorte, E. M. J., & Olinga, P. (2022) · Archives of Toxicology · doi:10.1007/s00204-022-03321-2 · Cited by 11
Idiosyncratic Drug-Induced Liver Injury: Mechanisms and Susceptibility Factors
Stephens, C., Lucena, M. I., & Andrade, R. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64089-8 · Cited by 16
Deng, Y., Luo, X., Li, X., Xiao, Y., Xu, B., & Tong, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.925509 · Cited by 12
Beaudoin, J. J., Yang, K., Adiwidjaja, J., Taneja, G., Watkins, P. B., Siler, S. Q., Howell, B. A., & Woodhead, J. L. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1085621 · Cited by 11
“, multidrug resistanceassociated protein (MRP) 3, MRP4, organic solute transporter (OST) α/β) is believed to contribute to this phenomenon, inhibition of the canalicular bile salt export pump (BSEP) is most often implicated (Morgan et al., 2013; Aleo et al., 2017; Beaudoin et al., 2020).”
BackgroundYang, K., Kong, R., Spiegel, R. J., Baird, J. D., O’Keefe, K., Howell, B. A., & Watkins, P. B. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3136 · Cited by 11
“…in vitro potency parameters (e.g., IC 50 and K i ) based on clinical exposure (e.g., C max , C ss ) has shown to be useful in identifying compounds with clinical DILI liabilities in early development phases, 15,18 these static approaches have limited utility in optimization of clinical trials.”
MethodFan, F., Hu, R., Munzli, A., Chen, Y., Dunn, R. T., Weikl, K., Strauch, S., Schwandner, R., Afshari, C. A., Hamadeh, H. K., et al. (2015) · Toxicological Sciences · doi:10.1093/toxsci/kfv052 · Cited by 11
“…toxin aValues in parenthesis are from coactivator recruitment assay where full-curve measurements were carried out; values in square brackets are from competition binding assay, for which single dose of 10 mM was used in all measurements. bCss values were from Morgan et al. (2013).”
MethodSelf-citationden Hof, W. F. P. M. V., Coonen, M. L. J., van Herwijnen, M. H. M., Brauers, K. J. J., Jennen, D. G. J., Damink, S. W. M. O., Schaap, F. G., & Kleinjans, J. C. S. (2017) · Toxicology in Vitro · doi:10.1016/j.tiv.2017.07.024 · Cited by 11
Function and Expression of Bile Salt Export Pump in Suspension Human Hepatocytes
Chothe, P. P., Pemberton, R., & Hariparsad, N. (2021) · Drug Metabolism and Disposition · doi:10.1124/dmd.120.000057 · Cited by 11
“In addition to BSEP, troglitazone is also an inhibitorof NTCP, OATPs(Guiet al., 2008, 2009; Yang et al., 2015), MRP3 (IC 50 : 31 m M), and MRP4 (IC 50 : 61 m M) (Morgan et al., 2013).”
Marroquin, L. D., Bonin, P. D., Keefer, J., & Schroeter, T. (2017) · Current Protocols in Toxicology · doi:10.1002/cptx.15 · Cited by 11
“Other hepatobiliary transporters, such as multi-drug-resistanceassociated protein (MRP) 2, 3, and 4, are hypothesized to compliment BSEP and increase DILI potential (Morgan et al., 2013).”
BackgroundIto, S., Lee, W., Park, J. E., Yasunaga, M., Mori, A., Ohtsuki, S., & Sugiyama, Y. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.10.064 · Cited by 11
Effect of mTOR inhibitors on sodium taurocholate cotransporting polypeptide (NTCP) function in vitro
Saran, C., Ho, H. S. S., Honkakoski, P., & Brouwer, K. L. R. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1147495 · Cited by 10
Lenhard, S. C., Lev, M., Webster, L. O., Peterson, R. A., Goulbourne, C. N., Miller, R. T., & Jucker, B. M. (2015) · Toxicologic Pathology · doi:10.1177/0192623315608509 · Cited by 10
“Amiodarone is not an mrp2 inhibitor in humans (Morgan et al. 2013), and the drug levels in this study did not reach a concentration required to inhibit mrp2 in rats.”
BackgroundIn vitro assessment of farnesoid X receptor antagonism to predict drug-induced liver injury risk
Norona, L. M., Fullerton, A. M., Lawson, C., Leung, L., Brumm, J., Kiyota, T., Maher, J. M., Khojasteh, C., & Proctor, W. R. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02804-4 · Cited by 12
A Robust, Mechanistically Based In Silico Structural Profiler for Hepatic Cholestasis
Firman, J. W., Pestana, C. B., Rathman, J. F., Vinken, M., Yang, C., & Cronin, M. (2020) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.0c00465 · Cited by 10
Ali, I., Khalid, S., Stieger, B., & Brouwer, K. L. R. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b01124 · Cited by 10
Melillo, N., Scotcher, D., Kenna, J. G., Green, C., Hines, C. D. G., Laitinen, I., Hockings, P. D., Ogungbenro, K., Gunwhy, E. R., Sourbron, S. P., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030896 · Cited by 9
Horiuchi, S., Kuroda, Y., Oyafuso, R., Komizu, Y., Maeda, K., & Ishida, S. (2024) · Archives of Toxicology · doi:10.1007/s00204-024-03757-8 · Cited by 9
“To overcome these limitations, the membrane vesicle assay (MVA) has been used to evaluate the DILI risk associated with the inhibition of biliary efflux transporter (Dawson et al. 2012; Morgan et al. 2013).”
Cheng, Y., Chen, S.-J., Freeden, C., Chen, W., Zhang, Y., Abraham, P., Nelson, D. M., Humphreys, W. G., Gan, J., & Lai, Y. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.242370 · Cited by 9
Gui, L., Wu, Q., Hu, Y., Zeng, W., Tan, X., Zhu, P., Li, X., Yang, L., Jia, W. P., Liu, C., et al. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00052 · Cited by 9
Donato, M. T., López-Riera, M., Castell, J. V., Gómez-Lechón, M. J., & Jover, R. (2016) · Toxicology Letters · doi:10.1016/j.toxlet.2016.10.008 · Cited by 9
Battista, C., Howell, B. A., Siler, S. Q., & Watkins, P. B. (2018) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-7677-5_6 · Cited by 9
Kochansky, C. J., Lyman, M., Fauty, S. E., Vlasáková, K., & D’mello, A. P. (2018) · Lipids · doi:10.1002/lipd.12110 · Cited by 10
Pinto, M., Machado, C. S., Barreiro, S., Otero-Espinar, F. J., Remião, F., Borges, F., & Fernandes, C. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c00614 · Cited by 8
Promoting Adoption of the 3Rs through Regulatory Qualification
Walker, E. G., Baker, A. F., & Sauer, J. M. (2016) · ILAR Journal · doi:10.1093/ilar/ilw032 · Cited by 8
“Building from Morgan et al. (2013) where over 600 marketed or withdrawn drugs were evaluated in BSEP expressing membrane vesicles, as well as multidrug resistance associated proteins also involved in bile acid homeostasis, the PSTC BSEP team is working to develop a translational framework linking…”
BackgroundBosentan Alters Endo- and Exogenous Bile Salt Disposition in Sandwich-Cultured Human Hepatocytes
Oorts, M., Brantegem, P. V., Deferm, N., Chatterjee, S., Dreesen, E., Cooreman, A., Vinken, M., Richert, L., & Annaert, P. (2021) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.121.000695 · Cited by 11
“(A) (Treiber et al., 2007); (B) (Lepist et al., 2014); (C) (Leslie et al., 2007); (D) (Morgan et al., 2010; Dawson et al., 2012); (E) (Mano et al., 2007); (F) (Morgan et al., 2013); (G) (Fouassier et al., 2002); (H) (Matuszewski et al., 2003).”
BackgroundVée, M. L., Moreau, A., Jouan, E., Denizot, C., Parmentier, Y., & Fardel, O. (2022) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2333 · Cited by 8
“The dual repression of canalicular and sinusoidal TC efflux by cholestatic compounds indicates that these chemicals may act through inhibiting both BSEP and MRP3/MRP4, as already suggested using vesicular assays (Köck et al., 2014; Morgan et al., 2013).”
BackgroundCyanide Trapping of Iminium Ion Reactive Metabolites: Implications for Clinical Hepatotoxicity
Miao, X., Dear, G. J., Beaumont, C., Vitulli, G., Collins, G. W., Gorycki, P. D., Harrell, A. W., & Sakatis, M. Z. (2024) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.3c00402 · Cited by 8
Li, Y., Evers, R., Hafey, M. J., Cheon, K., Duong, H., Lynch, D., LaFranco-Scheuch, L., Pacchione, S. J., Tamburino, A. M., Tanis, K. Q., et al. (2019) · Toxicological Sciences · doi:10.1093/toxsci/kfz079 · Cited by 8
A compound attributes-based predictive model for drug induced liver injury in humans
Liu, Y., Gao, H., & He, Y. D. (2020) · PLoS ONE · doi:10.1371/journal.pone.0231252 · Cited by 10
Zhuo, X., Howell, B. A., Shen, H., Woodhead, J. L., Mosure, K., Zhang, Y., Scialis, R. J., Iyer, R. A., Sun, Y., Boy, K. M., et al. (2023) · Toxicological Sciences · doi:10.1093/toxsci/kfad057 · Cited by 8
Kenna, J. G. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1290082 · Cited by 7
“Membrane vesicles isolated from insect cells transfected with cDNA encoding human BSEP enable quantification of human BSEP inhibition by drugs [58,59] and are especially useful for high volume compound screening.”
BackgroundInfluentialNiu, C., Xie, X., Liu, R., Liang, X., Hu, Y., & Lai, Y. (2024) · Drug Metabolism and Disposition · doi:10.1124/dmd.124.001675 · Cited by 8
“Further investigation is needed to determine the overall impact and identify the point of BA homeostasis disruption that leads to the development of DILI, using a system where the intestine-liver feedback mechanisms are present, which can only be studied in vivo.”
BackgroundInfluentialSakai, Y., Okumura, H., Iwao, T., Watashi, K., Ito, K., & Matsunaga, T. (2019) · Toxicology in Vitro · doi:10.1016/j.tiv.2019.104619 · Cited by 6
Ito, K., Sjöstedt, N., & Brouwer, K. L. R. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.119.088898 · Cited by 7
“The inhibition of MRP3 and MRP4 is a risk factor for drug-induced cholestasis (Morgan et al., 2013; Köck et al., 2014; Chan and Benet, 2018).”
BackgroundMethodInfluentialRecent Progress in Prediction Systems for Drug-induced Liver Injury Using In vitro Cell Culture
Ozawa, S., Miura, T., Terashima, J., Habano, W., & Ishida, S. (2020) · Drug Metabolism Letters · doi:10.2174/1872312814666201202112610 · Cited by 8
Transporters for Bile Formation in Physiology and Pathophysiology
Stieger, B. (2022) · CHIMIA International Journal for Chemistry · doi:10.2533/chimia.2022.1025 · Cited by 9
Kitaguchi, T., Horiuchi, S., Kuroda, Y., Ohno, K., Kobayashi, K., Tanaka, M., & Ishida, S. (2023) · The Journal of Toxicological Sciences · doi:10.2131/jts.48.251 · Cited by 7
A rare cause of a cholestatic jaundice in a North African teenager
Schreiner, P., Stieger, B., McLin, V. A., Rougemont, A., Keitel, V., Dröge, C., & Müllhaupt, B. (2019) · Liver International · doi:10.1111/liv.14122 · Cited by 7
Takemura, A., Gong, S., Sekine, S., & Ito, K. (2019) · Toxicology · doi:10.1016/j.tox.2019.05.004 · Cited by 8
Cao, M., Wang, L., Zhang, L., & Duan, J. (2021) · Science Progress · doi:10.1177/00368504211000535 · Cited by 7
Shah, F., Medvedev, A. V., Wassermann, A. M., Brodney, M. D., Zhang, L., Makarov, S. S., & Stanton, R. V. (2017) · Toxicological Sciences · doi:10.1093/toxsci/kfx231 · Cited by 7
Daood, N. J., Carey, S. R., Chung, E., Wang, T., Kreutz, A., Girireddy, M., Chakravarti, S., Kleinstreuer, N., Tiley, J. B., Aleksunes, L. M., et al. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c01065 · Cited by 8
“Similarly, an assay reported by Morgan et al. 76 assessing the inhibition of human MRP2 using [3 H ]-estradiol-17beta- D -glucuronide uptake in membrane vesicles was considered the largest contributor to the MRP2 ChEMBL data set, accounting for 637 out of 1192 entries.”
ABC gene-ranking for prediction of drug-induced cholestasis in rats
Cherkas, Y., McMillian, M., Amaratunga, D., Raghavan, N., & Sasaki, J. C. (2016) · Toxicology Reports · doi:10.1016/j.toxrep.2016.01.009 · Cited by 6
A Unique In Vitro Assay to Investigate ABCB4 Transport Function
Temesszentandrási‐Ambrus, C., Nagy, G., Bui, A., & Gáborik, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054459 · Cited by 6
“Inhibition of ABCB11 (Bile Salt Export Pump, BSEP) is a major risk factor in the development of cholestatic hepatotoxicity, though recent publications do not fully underscore this correlation [32,33].”
BackgroundLiu, H., Stresser, D. M., Michmerhuizen, M. J., Li, X., Othman, M. I. A., Reed, A. D., Schrimpf, M. R., Sydor, J. R., & Lee, A. J. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.117.077511 · Cited by 7
Tohyama, K., Chisaki, I., Takai, Y., Handa, Y., Miyamoto, M., & Amano, N. (2019) · Toxicological Sciences · doi:10.1093/toxsci/kfz093 · Cited by 6
Integration of in vitro and in silico approaches enables prediction of drug-induced liver injury
Geci, R., Sayin, A. Z., Schaller, S., & Kuepfer, L. (2026) · Archives of Toxicology · doi:10.1007/s00204-026-04305-2 · Cited by 7
Umemori, Y., Handa, K., Yoshimura, S., Kageyama, M., & Iijima, T. (2024) · Biomolecules · doi:10.3390/biom14050535 · Cited by 6
“In the cholestatic form, drugs can inhibit the bile salt export pump (BSEP), leading to the accumulation of bile acids in hepatocytes, resulting in toxicity [10,11].”
BackgroundLi, R., Kimoto, E., Bi, Y., Tess, D. A., & Varma, M. V. S. (2024) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01408-w · Cited by 5
“In the assay condition with rifamycin SV, both active processes (i.e., CL uptake,SCHH and CL bile,SCHH ) are assumed to be zero [11–13].”
Stephens, C. M., Lucena, M. I., & Andrade, R. J. (2018) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-7677-5_23 · Cited by 5
The C-DILI™ Assay: An Integrated In Vitro Approach to Predict Cholestatic Hepatotoxicity
Jackson, J. P., & Brouwer, K. R. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9420-5_5 · Cited by 5
Requirements for designing organ-on-a-chip platforms to model the pathogenesis of liver disease
Ishida, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-817202-5.00005-x · Cited by 6
Cell-based approaches for the mechanistic understanding of drug-induced cholestatic liver injury
Timor-López, E., Tolosa, L., & Donato, M. T. (2025) · Archives of Toxicology · doi:10.1007/s00204-025-04016-0 · Cited by 5
Feng, C., Ye, W., & Shan, Q.-W. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03701-w · Cited by 4
FXR: Big fish or small fry for drug-induced liver injury?
Ballet, F. (2016) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2015.11.008 · Cited by 4
Hill, D. J. (2017) · Wiley eBooks · doi:10.1002/9781119043805.ch29 · Cited by 5
Regulation of Hepatobiliary Transporters During Liver Injury
Manautou, J. E., & Ghanem, C. I. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.95661-7 · Cited by 3
Koga, T., Takeuchi, K., & Umehara, K. (2023) · The Journal of Toxicological Sciences · doi:10.2131/jts.48.47 · Cited by 3
Kastrinou‐Lampou, V., Rodríguez-Pérez, R., Poller, B., Huth, F., Schadt, H. S., Kullak-Ublick, G. A., Arand, M., & Camenisch, G. (2024) · Archives of Toxicology · doi:10.1007/s00204-024-03895-z · Cited by 4
“Results were only slightly improved when BSEP inhibition was added, despite its well-known association to DILI (Daw-son et al. 2012; Morgan et al. 2013; Yucha et al. 2017).”
Fardel, O., Moreau, A., Jouan, E., Denizot, C., Vée, M. L., & Parmentier, Y. (2025) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2025.2453486 · Cited by 3
“This dual repression of canalicular and sinusoidal efflux of taurocholate likely indicates that these compounds inhibit both BSEP and MRP3/MRP4, as already suggested using vesicular assays [9,107].”
InfluentialBassett, J. J., Balasubramanian, B., Clouse, H., & Trepakova, E. S. (2025) · Toxicology · doi:10.1016/j.tox.2025.154088 · Cited by 3
Targeting Drug Resistance in Cancer: Dimethoxycurcumin as a Functional Antioxidant Targeting ABCC3
Nelen, J., Naponelli, V., Villalgordo-Soto, J. M., Falasca, M., & Pérez‐Sánchez, H. (2025) · Antioxidants · doi:10.3390/antiox14050599 · Cited by 4
“BDBM50302828 was evaluated in a cell-free biochemical system designed to isolate transporter function [33], whereas dimethoxycurcumin’s activity was assessed using whole-cell viability assays.”
Olubamiwa, A. O., Ma, J., Dehanne, P., Noban, C., Angın, Y., Barberan, O., & Chen, M. (2025) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2025.2514537 · Cited by 3
“Factoring in drug in vivo exposure, using the steady-state concentration (C ss ), led to the proposal of the use of the cutoff value of C ss /BSEP IC 50 ratio ≥0.1 to classify drugs by their DILI potential [33].”
InfluentialCellular imaging: a key phenotypic screening strategy for predictive toxicology
Xu, J. J. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00191 · Cited by 3
Metadata
- Authors
- Morgan, R. E., van Staden, C. J., Chen, Y., Kalyanaraman, N., Kalanzi, J., Dunn, R. T., Afshari, C. A., & Hamadeh, H. K.
- Affiliations
- Amgen (United States) (US)
- Venue
- Toxicological Sciences
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-08-16
- Volume
- 136
- Issue
- 1
- Pages
- 216-241
- ISSN
- 1096-0929 (ISSN-L)
- 1096-6080
- OpenAlex
- W2152548885
- Cited by
- 243
- References
- 41
- Citations by year
- 2026: 12 · 2025: 19 · 2024: 14 · 2023: 14 · 2022: 15 · 2021: 13 · 2020: 12 · 2019: 24 · 2018: 20 · 2017: 33 · 2016: 30 · 2015: 24 · 2014: 11 · 2013: 2
- FWCI
- 11.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Toxicological Sciences (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- bile salt export pump, drug-induced liver injury, hepatotoxicity, bile acid transport, multidrug resistance-associated protein, MRP2, MRP3, MRP4, steady-state concentration, hepatobiliary transporters, drug safety assessment
- MeSH terms
- ATP Binding Cassette Transporter, Subfamily B, Member 11, Animals, Biological Transport, Humans, Liver, Male, Pharmacokinetics, Recombinant Proteins, Risk Factors, Cluster Analysis, Rats, Sprague-Dawley, ATP Binding Cassette Transporter, Subfamily B, ATP-Binding Cassette Transporters, Risk Assessment, Toxicity Tests, ATP-Binding Cassette, Sub-Family C Proteins, Rats, Chemical and Drug Induced Liver Injury, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.